特立帕肽在药物相关性颌骨坏死中治疗作用的研究进展

doi:10.12337/zgkqjxjyzz.2025.05.001

中国口腔医学继续教育杂志 ›› 2025, Vol. 28 ›› Issue (5): 297-306.DOI: 10.12337/zgkqjxjyzz.2025.05.001

• 综述 • 下一篇

特立帕肽在药物相关性颌骨坏死中治疗作用的研究进展

丁一辉¹, 王丹丹², 李晨璐², 王继弘², 田磊^2,*, 宗春琳^2,*

¹空军军医大学学员队四大队十六队;
²口颌系统重建与再生全国重点实验室,国家口腔疾病临床医学研究中心,陕西省口腔疾病临床医学研究中心,空军军医大学第三附属医院口腔颌面外科

出版日期:2025-09-30 发布日期:2025-09-30
通讯作者: ^* 宗春琳、田磊,联系方式：029-84776109,电子邮箱：mujiezi23@163.com,tianleison@163.com;通讯地址：陕西省西安市新城区长乐西路145号,710032
基金资助:
陕西省重点研发计划,Fe₃O₄磁性纳米颗粒诱导BMMSCs来源外泌体在放射性颌骨损伤治疗中的作用及机制研究（项目编号：2024SF-YBXM-264）; 空军军医大学临床研究项目,自体浓缩生长因子对药物相关性颌骨坏死术后伤口作用的临床试验研究（项目编号：2022LC2239）

Effect of Teriparatide on Therapy of Medication-related Osteonecrosis of the Jaw

Yihui Ding¹, Dandan Wang², Chenlu Li², Jihong Wang², Lei Tian^2,*, Chunlin Zong^2,*

¹Sixteenth Team, Fourth Cadet Regiment, Air Force Medical University, Xi’an, Shaanxi Province, P.R. China;
²State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases & Shaanxi Clinical Research Center for Oral Diseases & Department of Oral and Maxillofacial Surgery, School of Stomatology, The Third Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi Province, P.R. China

Online:2025-09-30 Published:2025-09-30
Contact: Chunlin Zong, Lei Tian. Tel: 029-84776109. Emails: mujiezi23@163.com; tianleison@163.com. Address: No. 145 Changle West Road, Xincheng District, Xi’an 710032, Shaanxi Province, P.R. China.

摘要/Abstract

摘要： 药物相关性颌骨坏死（medication-related osteonecrosis of the jaw,MRONJ）是应用抗骨吸收、抗血管生成等药物后出现的一种严重并发症,手术切除死骨治疗易复发,抗生素、高压氧等保守治疗效果不理想。近年来学者发现特立帕肽对MRONJ有治疗作用。本文通过文献综述,阐述MRONJ的诊断标准和分期,归纳特立帕肽对MRONJ的治疗效果、给药方式、联合应用及可能的治疗机制,为特立帕肽治疗MRONJ 的临床应用与科学研究提供依据与参考。

Abstract: Medication related osteonecrosis of the jaw (MRONJ) is a serious complication that occurs after the use of anti bone resorption, anti angiogenesis, and other drugs.In recent years, scholars have found that Teriparate has therapeutic effects on MRONJ. This article elaborates on the diagnostic criteria and staging of MRONJ through literature review, summarizes the therapeutic effects, administration methods, combination therapy, and possible treatment mechanisms of Teriparate for MRONJ, and provides a basis and reference for the clinical application and scientific research of Teriparate in the treatment of MRONJ.

Key words: medication-related osteonecrosis of the jaw, teriparatide, conservative treatment, drug therapy, bone metabolism-related diseases

丁一辉, 王丹丹, 李晨璐, 王继弘, 田磊, 宗春琳. 特立帕肽在药物相关性颌骨坏死中治疗作用的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 297-306.

Yihui Ding, Dandan Wang, Chenlu Li, Jihong Wang, Lei Tian, Chunlin Zong. Effect of Teriparatide on Therapy of Medication-related Osteonecrosis of the Jaw[J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 297-306.

参考文献

[1] Ruggiero SL, Dodson TB, Aghaloo T, et al.American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update[J]. J Oral Maxillofac Surg, 2022, 80(5):920-943.
[2] 何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21(4):313-325.
[3] Ruan HJ, Chen H, Hou JS, et al.Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw[J]. J Bone Oncol, 2024, 12(49):100650.
[4] 中华口腔医学会. 接受双膦酸盐治疗患者拔牙围手术期处理专家共识: T/CHSA081-2024[S]. 北京: 中国质量标准出版传媒有限公司; 中国标准出版社, 2024:32-43.
[5] Beth-Tasdogan NH, Mayer B, Hussein H, et al. Interventions for managing medication-related osteonecrosis of the jaw[J]. Cochrane Database Syst Rev, 2022, 07(12):CD012432.
[6] On SW, Cho SW, Byun SH, et al.Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches[J]. Antioxidants (Basel), 2021, 10(5):680.
[7] Abdolrahmani A, Epstein JB, Samim F.Medication-related osteonecrosis of the jaw: Evolving research for multimodality medical management[J]. Supportive Care Cancer, 2024, 32(4):212.
[8] Sim IW, Borromeo GL, Tsao C, et al.Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: A placebo-controlled, randomized trial[J]. J Clin Oncol, 2020, 38(26):2971-2980.
[9] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1157.
[10] Kyrgidis A, Toulis KA.Denosumab-related osteonecrosis of the jaws[J]. Osteoporos Int, 2011, 22(1): 369-370.
[11] Greuter S, Schmid F, Ruhstaller T, et al.Bevacizumab-associated osteonecrosis of the jaw[J]. Ann Oncol, 2008, 19(12):2091-2092.
[12] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication related osteonecrosis of the jaws-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10):1938-1956.
[13] Chen YJ, Wang SP, Cheng FC, et al.Intermittent parathyroid hormone improve bone microarchitecture of the mandible and femoral head in ovariectomized rats[J]. BMC Musculoskelet Disord, 2017, 18(1):171.
[14] Li JY, Yu M, Tyagi AM, et al.IL-17 Receptor Signaling in Osteoblasts/Oseocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production[J]. J Bone Mineral Res, 2019, 34(2):349-360.
[15] Chen T, Wang Y, Hao Z, et al.Parathyroid hormone and its related peptides in bone metabolism[J]. Biochem Pharmacol, 2021, 192:114669.
[16] Casado E, Martínez-Díaz-Guerra G, Caeiro JR. PTH/PTHrP analogues as osteoanabolic treatment in patients with osteoporosis[J]. Med Clin (Barc), 2025, 165(4):107076. English, Spanish.
[17] Harper RP, Fung E.Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone rhPTH(1-34)[J]. J Oral Maxillofac Surg, 2007, 65(3):573-580.
[18] Morishita K, Yamada SI, Kawakita A, et al.Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan[J]. J Orthop Sci, 2020, 25(6):1079-1083.
[19] Dos Santos Ferreira L, Abreu LG, Calderipe CB, et al. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis[J]. Osteoporos Int, 2021, 32(12):2449-2459.
[20] Singh A, Chung K, Huryn JM, et al.Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2025, 140(3):e59-e63.
[21] Kim RY, Hong SO, Jung JW, et al.Successful treatment of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw: A report of two cases[J]. J Korean Assoc Oral Maxillofac Surg, 2024, 50(5):285-291.
[22] Choi SY, Yoon D, Kim KM, et al.Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: A report of three cases[J]. J Korean Assoc Oral Maxillofac Surg, 2024, 50(2):103-109.
[23] Mohamed MM, Gunasekera WM, Glew D, et al.Teriparatide therapy for medication-related osteonecrosis of the jaw: Case report and literature review[J]. Clin Med (Lond), 2022, 22(Suppl 4):20-21.
[24] Ohbayashi Y, Iwasaki A, Nakai F, et al.A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration[J]. Osteoporos Int, 2020, 31(3):577-585. Erratum in: Osteoporos Int, 2025, 36(1):159-160.
[25] Kim KM, Kim S, Hwang H, et al.Effects of daily versus weekly teriparatide for medication-related osteonecrosis of the jaw: A case-control study[J]. Oral Dis, 2024, 30(5):3286-3295.
[26] Yoshiga D, Yoshioka I, Habu M, et al.Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: A clinical case series[J]. Br J Oral Maxillofac Surg, 2022, 60(5):604-609.
[27] Jung J, Yoo HY, Kim GT, et al.Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study[J]. J Bone Miner Res, 2017, 32(12):2445-2452.
[28] Bassan Marinho Maciel G, Marinho Maciel R, Linhares Ferrazzo K, et al. Etiopathogenesis of medication-related osteonecrosis of the jaws: a review[J]. J Mol Med (Berl), 2024, 102(3):353-364.
[29] Radović K, Brković B, Roganović J, et al.Salivary VEGF and Post-Extraction Wound Healing in Type 2 Diabetic Immediate Denture Wearers[J]. Acta Odontol Scand, 2022, 80(1):9-14.
[30] Vallina C, Ramírez L, Torres J, et al.Osteonecrosis of the jaws produced by sunitinib: a systematic review[J]. Med Oral Patol Oral Cir Bucal, 2019, 24(3):e326-e338.
[31] Badel T, Pavicin IS, Carek AJ, et al.Pathophysiology of osteonecrosis of the jaw in patients treated with bisphosphonate[J]. Coll Antropol, 2013, 37(2):645-651.
[32] Zandi M, Dehghan A, Mohammadi-Mofrad A, et al.Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats[J]. J Craniomaxillofac Surg, 2017, 45(2):275-280.
[33] Jung J, Shim GJ, Kim M, et al.Effect and timing of parathyroid hormone analog administration for preventing medication-related osteonecrosis of the jaws in a murine model[J]. J Craniomaxillofac Surg, 2021, 49(8):719-725.
[34] Keskinruzgar A, Bozdag Z, Aras MH, et al.Histopathological Effects of Teriparatide in Medication-Related Osteonecrosis of the Jaw: An Animal Study[J]. J Oral Maxillofac Surg, 2016, 74(1):68-78.
[35] Liu J, Mattheos N, Deng C, et al.Management of medication-related osteonecrosis of jaw: Comparison between icariin and teriparatide in a rat model[J]. J Periodontol, 2021, 92(1):149-158.
[36] Nakanishi-Kimura A, Takakura A, Hoshi-Numahata M, et al.Dynamic morphometric changes in the mandibular osteocytic lacunae of ovariectomized rats in response to teriparatide, as revealed by three-dimensional fluorescence analyses: Possible involvement of osteocytic perilacunar remodeling[J]. J Oral Biosci, 2024, 66(1): 49-60.
[37] Hasegawa T, Hayashida S, Kondo E, et al; Japanese Study Group of Co-operative Dentistry with Medicine (JCDM). Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study[J]. Osteoporos Int, 2019, 30(1):231-239.
[38] Moreno-Rabié C, Lapauw L, Gaêta-Araujo H, et al.Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction[J]. Sci Rep, 2022, 12(1):11280.
[39] Schwech N, Nilsson J, Gabre P.Incidence and risk factors for medication-related osteonecrosis after tooth extraction in cancer patients-A systematic review[J]. Clin Exp Dent Res, 2023, 9(1):55-65.
[40] Kwoen MJ, Park JH, Kim KS, et al.Association Between Periodontal Disease, Tooth Extraction, and Medication-Related Osteonecrosis of the Jaw in Women Receiving Bisphosphonates: A National Cohort-Based Study[J]. J Periodontol, 2023, 94(1):98-107.
[41] Li Q, Pu Y, Lu H, et al.Porphyromonas, Treponema, and Mogibacterium promote IL8/IFNγ/TNFα-based pro-inflammation in patients with medication-related osteonecrosis of the jaw[J]. J Oral Microbiol, 2020, 13(1):1851112.
[42] Wu S, Li F, Tan J, et al.Porphyromonas gingivalis induces bisphosphonate-related osteonecrosis of the Femur in mice[J]. Front Cell Infect Microbiol, 2022, 12: 886411.
[43] López-Jornet P, Camacho-Alonso F, Martínez-Canovas A, et al.Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws[J]. J Oral Maxillofac Surg, 2011, 69(10):2488-2493.
[44] Abtahi J, Agholme F, Aspenberg P.Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model[J]. Int J Oral Maxillofac Surg, 2013, 42(5):632-636.
[45] Zheng Y, Dong X, Chen S, et al.Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing[J]. BMC Oral Health, 2023, 23(1):14.
[46] Troeltzsch M, Zeiter S, Arens D, et al.Chronic Periodontal Infection and Not Iatrogenic Interference Is the Trigger of Medication-Related Osteonecrosis of the Jaw: Insights from a Large Animal Study (PerioBRONJ Pig Model)[J]. Medicina (Kaunas), 2023, 59(5):1000.
[47] Udeabor SE, Heselich A, Al-Maawi S, et al.Current Knowledge on the Healing of the Extraction Socket: A Narrative Review[J]. Bioengineering (Basel), 2023, 10(10):1145.
[48] Hayano H, Kuroshima S, Sasaki M, et al.Distinct immunopathology in the early stages between different antiresorptives related osteonecrosis of the jaw-like lesions in mice[J]. Bone, 2020, 135:115308.
[49] Jiang A, Zhang Z, Qiu X, et al.Medication-related osteonecrosis of the jaw (MRONJ): A review of pathogenesis hypothesis and therapy strategies[J]. Arch Toxicol, 2024, 98(3):689-708.
[50] Kuroshima S, Al-Omari FA, Sasaki M, et al.Medication-related osteonecrosis of the jaw: A literature review and update[J]. Genesis, 2022, 60(8-9):e23500.
[51] Kaur K, Kanayama K, Wu QQ, et al.Zoledronic acid mediated differential activation of NK cells in different organs of WT and Rag2(-/-) mice stark differences between the bone marrow and gingivae[J]. Cell Immunol, 2022, 375:104526.
[52] Yang G, Collins JM, Rafiee R, et al.SIRT1 gene SNP rs932658 is associated with medication-related osteonecrosis of the jaw[J]. J Bone Miner Res, 2021, 36(2):347-356.
[53] Kim S, Mun S, Shin W, et al.Identification of potentially pathogenic variants associated with recurrence in medication-related osteonecrosis of the jaw (MRONJ) patients using whole-exome sequencing[J]. J Clin Med, 2022, 11(8):2145.

特立帕肽在药物相关性颌骨坏死中治疗作用的研究进展

Effect of Teriparatide on Therapy of Medication-related Osteonecrosis of the Jaw

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	何金媛, 孙国文. 药物相关性颌骨坏死的机制及治疗研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 307-311.
[2]	徐冰玥, 鲁涵, 刘柯蓥, 何巍. 药物相关性颌骨坏死中微生态失衡的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 312-321.
[3]	张逸云, 康非吾, 张雪明. 药物相关性颌骨坏死非手术治疗的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 322-330.
[4]	江晨曦, 孙国文. 药物相关性颌骨坏死临床诊疗的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 331-336.
[5]	王睿, 孙国文. 3期药物相关性颌骨坏死的手术治疗的回顾性研究[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 345-352.
[6]	何金媛, 孙国文. 斜面导板改善下颌骨药物相关性颌骨坏死的咬合关系1例[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 360-366.
[7]	李娜, 常远, 高宁, 付坤, 蔡菁华, 高振杰, 乔翔鹤, 杨雷雷, 何巍. 药物相关性颌骨坏死的“互联网+”案例教学法的临床应用[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 367-374.
[8]	释栋, 于晨浩, 司燕, 宋忠臣, 欧阳翔英, 刘怡, 胡文杰, 潘亚萍. 中国牙周健康管理现状与未来策略[J]. 中国口腔医学继续教育杂志, 2025, 28(4): 189-193.